Melinda French Gates called for greater investment in women's health and urged policymakers and advocates to use their voices to drive change [1].

This push for reform addresses a long-standing gap in medical research where women have historically received less focus and funding than men. Because women's health needs differ biologically and hormonally, the lack of targeted investment can lead to poorer health outcomes and less effective treatments.

Speaking at the Forbes Power Women's Summit in 2026 [3], Gates said that the current pace of progress is insufficient. "The time for incrementalism is over," Gates said [1]. She emphasized that leaders must move beyond small steps to achieve systemic changes in how healthcare is funded and researched.

The disparity in medical attention is reflected in clinical data. While women make up 51% of the world's population [4], they are significantly underrepresented in medical testing. Nearly 89% of participants in clinical trials are men [5]. This gap means that many medical breakthroughs are based on male biology, often leaving women with treatments that are not optimized for their specific needs.

Advocates note that the scope of women's health must expand beyond reproductive care. Hormonal health, for example, affects every stage of a woman's life [6]. By focusing primarily on pregnancy and childbirth, the medical establishment has often overlooked chronic conditions, and hormonal imbalances that impact women from adolescence through menopause.

Gates highlighted the need for a personalized approach to medicine to ensure that the 51% of the global population [4] receives care tailored to their biology. Following her initial call to action, a follow-up event was scheduled for September 2026 to further the conversation on funding and advocacy [1].

The movement seeks to shift the paradigm from a one-size-fits-all medical model to one that recognizes the distinct physiological requirements of women. Gates said that the global community must prioritize this investment to ensure equitable health outcomes for all.

“"The time for incrementalism is over."”

The call for increased investment in women's health highlights a systemic bias in biomedical research known as the 'gender data gap.' When the vast majority of clinical trials rely on male subjects, the resulting medical standards may be inaccurate or unsafe for women. Shifting toward a personalized, gender-specific approach to healthcare could lead to more accurate diagnoses and more effective pharmaceutical treatments for half the global population.